WHOOP expands women’s health offering with biomarker panel and hormonal insights

New updates have been reported about WHOOP.

WHOOP is broadening its women’s health strategy with a new blood-testing panel under its WHOOP Labs service and a menstrual-cycle analytics feature embedded in its app. The women’s health panel, available for purchase next month, measures 11 biomarkers, including AMH, progesterone, prolactin, thyroid-related antibodies and hormones, leptin, vitamin B12, folate, magnesium, and phosphate, aimed at explaining cycle regularity, hormonal transitions, and broader metabolic and nutrient status.

By combining these blood markers with WHOOP’s existing sleep, recovery, and activity data, the company says it can provide more actionable insight into perimenopause, thyroid function, nutrient sufficiency, and bone health risk. A new Hormonal Symptom Insights and Predictions feature builds individualized models of menstrual cycles, projecting likely period windows, identifying irregularities, and linking symptom patterns to underlying physiology, while categorizing lab results as optimal, sufficient, or out of range.

WHOOP has published a menstrual-cycle white paper outlining the modeling behind these tools, signaling a push to position itself as a data-driven platform for women’s performance and health rather than a generic fitness wearable. The launch also capitalizes on strong user momentum: the company reports a 150% year-over-year increase in women using its products, now its fastest-growing segment, and notes that women interact with its WHOOP AI 30% more than other users.

Strategically, this deepens WHOOP’s differentiation in an increasingly competitive wearables market where women’s health has been historically under-served but is now a focal growth area. The expanded service stack—hardware, continuous monitoring, AI-driven cycle analytics, and paid lab testing—creates additional monetization opportunities and potential for higher retention among female members. For investors and partners, these moves indicate a deliberate shift toward more clinical-grade, subscription-friendly services, which could support higher ARPU and open doors to collaborations in women’s health, digital therapeutics, and employer or payer-sponsored wellness programs.